Dengue Literature Review

Coagulation and Fibrinolysis in Dengue

7 min read

Coagulation and Fibrinolysis in Dengue

Overview

Dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) are characterised by a coagulopathy involving prolonged activated partial thromboplastin time (APTT), reduced fibrinogen, and elevated fibrin degradation products. Several mechanisms operate in parallel: (1) direct NS1 protein effects (sNS1 binds thrombin and inhibits prothrombin activation); (2) cross-reactive auto-antibodies generated via molecular mimicry between DENV proteins and coagulation/fibrinolytic factors; and (3) glycocalyx shedding releasing anticoagulant heparan sulfate into circulation. This page focuses on the auto-antibody-mediated mechanism — the profibrinolysis/hyperfibrinolysis axis — which is mechanistically distinct from the direct NS1 effects covered in Dengue Pathophysiology.

Key Points from Literature

Structural basis for coagulation factor mimicry

Sequence analysis reveals at least 12 regions within DENV proteins (NS1, core, prM, E) that share amino acid homology with coagulation and fibrinolytic factors including factors X, XI, VII, IX, II (thrombin), plasminogen, and tissue plasminogen activator (tPA). Two complementary approaches document this mimicry: (1) direct linear amino acid sequence comparison between DENV proteins and coagulation factor sequences; (2) in silico conformational analysis identifying shared structural motifs.

The most specific documented instance is a six-amino-acid motif in the E protein (WGNGCG, aa 101–106) sharing sequence similarity with coagulation Factor XI (positions 439–444: WGEGCA). This motif is conserved in haemorrhagic flaviviruses (JEV, WNV, YFV, TBE, OHFV) but absent in HCV, which does not typically cause haemorrhagic disease — providing independent molecular evidence linking this motif to the flavivirus haemorrhagic phenotype. (see Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis, E Protein)

Markoff et al. (1991) published the first report demonstrating auto-antibodies against a coagulation factor (plasminogen) in dengue patient sera — predating the molecular characterisation of the mimicry mechanism. (see Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review, review citing Markoff 1991)

Profibrinolysis mechanism

In profibrinolysis, auto-antibodies bind plasminogen and act directly on fibrinogen — causing regulated breakdown of fibrinogen. The auto-antibody here functions as a cofactor for plasminogen-mediated fibrinogenolysis rather than causing uncontrolled fibrin degradation. The downstream effect is abnormal loss of fibrinogen from the clotting cascade, contributing to hypocoagulability. (see Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review, citing Chuang 2013)

Hyperfibrinolysis mechanism

In hyperfibrinolysis, auto-antibodies bind the plasminogen complex — converting the mechanism from fibrinogenolysis to fibrinolysis. This produces excessive fibrin degradation products (FDP) by accelerating breakdown of already-formed fibrin clots, resulting in a bleeding tendency. In clinical terms: DHF/DSS patients with hyperfibrinolysis show decreased fibrinogen AND elevated FDP — the laboratory signature of this pathway. (see Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review, citing Chuang 2013)

The two mechanisms are mechanistically related but distinct in target (fibrinogen vs. fibrin clot) and consequence (regulated fibrinogenolysis vs. uncontrolled fibrinolysis). Whether a given patient’s coagulopathy is dominated by profibrinolysis or hyperfibrinolysis may depend on the titre, specificity, and functional properties of their anti-plasminogen antibody population — this has not been directly tested in patient cohorts.

scFv experimental evidence — NS1 cross-reactivity with fibrinogen

Chuang et al. (2014) generated recombinant single-chain variable fragments (scFv) from NS1-immunised mice and selected for fibrinogen cross-reactive clones. Key results:

  • Fibrinogen cross-reactive scFv antibodies were isolated from the library — confirming NS1 can generate auto-antibodies with fibrinogen reactivity
  • scFv anti-NS1/fibrinogen increased fibrinogen activation and prolonged thrombin time in vitro
  • Recombinant scFv against NS1 interfered with fibrin production → prolonged thrombin time beyond normal range

These results provide in vitro mechanistic proof that NS1 molecular mimicry can generate auto-antibodies functionally capable of disrupting coagulation at the fibrin formation step — independent of the E protein/plasminogen mechanism. (see Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review, citing Chuang 2014)

Important caveat: The scFv experiments used engineered monoclonal fragments, not natural patient antibody populations. Whether serum-level polyclonal anti-plasminogen and anti-fibrinogen auto-antibodies in natural dengue infection achieve sufficient concentration and affinity to produce the same effects is not established from patient cohort data.

Clinical coagulopathy markers

In DENV-infected patients with DHF:

  • Prolonged APTT and thrombin time
  • Decreased fibrinogen levels
  • Elevated fibrin degradation products (FDP) / D-dimer — indicating active fibrinolysis
  • APTT is the strongest laboratory correlate of vascular permeability in dengue patients (see Dengue Pathophysiology)

These markers are consistent with both the direct NS1-thrombin binding mechanism (sNS1 inhibits prothrombin activation → reduced fibrin formation → prolonged APTT) and the auto-antibody-mediated profibrinolysis/hyperfibrinolysis mechanism. Distinguishing the relative contributions of each requires studies that directly measure anti-plasminogen/anti-fibrinogen autoantibody titres alongside these markers — which has not been done in cohort-scale studies in this wiki.

Correlation with plasminogen cross-reactive antibodies and haemorrhage

Multiple studies have documented a correlation between plasminogen cross-reactive antibodies and haemorrhage in DENV-infected patients (cited in Ghorai2024 via Warter et al. 2012). This represents direct epidemiological support — not just mechanistic hypothesis — for the profibrinolysis/hyperfibrinolysis pathway contributing to clinical haemorrhagic manifestations.

Coagulation mimicry versus platelet mimicry: two distinct auto-antibody pathways

The DENV-induced coagulation/fibrinolysis disruption (anti-plasminogen/anti-fibrinogen, driven by prM, E, NS1, and core homology with coagulation factors) is mechanistically distinct from the thrombocytopenia pathway (anti-platelet IgM via NS1 C-terminal P311–330 mimicry of PDI/HSP60/vimentin). Both arise from DENV molecular mimicry but target different host systems and produce different pathological outputs:

PathwayPrimary auto-antibodyTargetConsequence
Platelet mimicryIgM anti-platelet (anti-NS1)PDI, HSP60, vimentin on platelet surfaceComplement-mediated platelet lysis → thrombocytopenia
Coagulation mimicryAnti-plasminogen/fibrinogen (anti-NS1/E/prM)Plasminogen, fibrinogen (soluble)Profibrinolysis or hyperfibrinolysis → bleeding tendency

The bleeding tendency in DHF therefore has at least two contributing auto-antibody mechanisms that may compound each other: thrombocytopenia (quantitative platelet deficit) and hyperfibrinolysis (qualitative coagulation factor dysfunction). In clinical DHF, both are typically present, making it difficult to determine which is dominant in any individual case.

Vaccine design implication

Since dengue vaccine designers should avoid epitopes that mimic coagulation factors, the prM, E, and NS1 sequences that share homology with coagulation factors are candidate exclusion targets — complementing the already-identified P311–330 NS1 exclusion for anti-PDI autoantibody risk (see NS1 Molecular Mimicry in Dengue, Dengue Vaccine Candidates).

Contradictions & Debates

  • scFv vs. polyclonal antibodies: The Chuang 2014 scFv studies demonstrate coagulation interference in vitro with engineered monoclonal fragments. Whether natural polyclonal anti-dengue antibodies achieve sufficient anti-plasminogen/anti-fibrinogen titres to reproduce these effects in vivo is not established.
  • DIC vs. non-DIC classification in dengue: The haemostatic profile of DHF resembles but does not fully meet criteria for classic disseminated intravascular coagulation (DIC). The profibrinolysis/hyperfibrinolysis model provides an alternative mechanistic explanation for the coagulopathy distinct from classic DIC — potentially resolving the diagnostic debate.
  • Relative contribution vs. direct NS1 effects: sNS1 also directly inhibits prothrombin activation and prolongs APTT (Guzman2016). Whether the auto-antibody-mediated mechanism is additive, redundant, or dominant relative to direct NS1 coagulation effects has not been disentangled clinically.

Sources

  • Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis (WGNGCG E protein motif homology to coagulation factors XI, X, IX, VII, thrombin, plasminogen, tPA; anti-E Abs inhibit plasmin; 12 DENV sequence regions with coagulation homology; NCKU Taiwan)
  • Guzman2016 - Dengue Infection (direct NS1 coagulation effects: sNS1-thrombin binding in vivo; APTT as strongest vascular permeability correlate; glycocalyx heparan sulfate shedding anticoagulant contribution; clinical coagulopathy markers in DHF)
  • Wan2012 - Autoimmunity in Dengue Pathogenesis (capstone NCKU review citing molecular mimicry between NS1/E/prM and coagulation molecules as contributing to haemostatic disruption; review context)
  • Ghorai2024 - Autoantibodies in Dengue Pathogenesis Review (profibrinolysis and hyperfibrinolysis dual mechanism via anti-plasminogen auto-antibodies; scFv NS1→fibrinogen cross-reactivity prolongs thrombin time; anti-plasminogen/haemorrhage correlation; Markoff 1991 historical first report; DHF clinical coagulopathy markers; review, Kolkata India)

Graph View

Backlinks